Genzyme Board Sued Over Drug Delays, Insider Deals
Members of Genzyme Corp.'s board of directors are the target of a shareholder derivative suit filed on Tuesday alleging that they caused the company to issue misleading statements about its compliance...To view the full article, register now.
Already a subscriber? Click here to view full article